Concerns Over Delayed Warnings About Vaccine-Related Risks
In a recent interim report from Sen. Ron Johnson’s office, it has been claimed that health officials delayed warnings to the public for several months in 2021 regarding the risks of cardiac complications linked to the mRNA covid-19 vaccine.
Since February 2021, federal health agencies reportedly received multiple alerts about instances of myocarditis in young individuals who were vaccinated with the Pfizer Covid-19 vaccine. However, it wasn’t until late June of that year that changes were made to the vaccine’s label to inform the public about these side effects.
The report, spanning 54 pages, asserts, “Despite being aware of myocarditis risks following the Covid-19 vaccine, the Biden administration chose not to issue official warnings for several months, potentially jeopardizing the health of young Americans.”
Myocarditis refers to inflammation of the heart muscle, while pericarditis is inflammation of the outer sac surrounding the heart. Some patients experiencing these side effects generally see their symptoms improve over time, as noted by the Centers for Disease Control and Prevention.
It was noted within the report that top health officials were hesitant to address data regarding myocarditis risks, avoiding a role as “vigilators.”
On February 28, 2021, the Israeli Ministry of Health reached out to the CDC and FDA to discuss concerns about myocarditis and heart-related issues in young people receiving the Pfizer vaccine. At that moment, Israel’s vaccination rates were significantly higher than those in the U.S.
About ten days later, the FDA’s initial response pointed to the challenges posed by incomplete data and passive surveillance, making it difficult to establish a causal link. U.S. health officials then sought additional data from Israeli counterparts.
By mid-April, a contractor for the Department of Defense highlighted findings from a working group, suggesting that “cardiac symptoms post-vaccination are likely indicative of hypersensitivity eosinophilic myocarditis.” This came after over 158 cases of myocarditis, pericarditis, and related conditions were logged in the Vaccine Adverse Event Reporting System (VAERS).
The following month, as the Covid-19 vaccine gained approval for younger audiences, there was a push to ensure that information about myocarditis reporting was communicated effectively to healthcare providers.
Discussions among top health authorities also emerged regarding the National Health Warning Network (HAN) and its advisories about vaccine-related myocarditis and pericarditis.
Internal communications showed that significant doubts persisted around the necessity of issuing widespread warnings. For instance, Dr. Sarah Oliver from the CDC characterized the ongoing dialogue about the official warnings as critical as of May 25, 2021.
Shortly after, former FDA Commissioner Dr. Janet Woodcock expressed concerns via email about escalating warnings without appropriate grounding.
Other health officials echoed similar hesitations, including concerns stated by Peter Marks regarding the lack of definitive knowledge surrounding myocarditis and pericarditis risks.
Johnson’s report revealed these internal exchanges among health authorities, Pfizer, and Moderna, outlining the deliberative processes involved. Rather than pushing out a HAN warning, the CDC opted for a different notification route on May 28, 2021, which acknowledged the heightened incidence of myocarditis and pericarditis in the U.S. but continued to endorse vaccinations for those aged 12 and older.
By this time, VAERS reported a rise to 752 cases. Then, on June 25, 2021, the FDA updated the labeling for Pfizer and Moderna vaccines to highlight these risks.
This period’s internal discussions about myocarditis occurred amidst a pressing global pandemic, which intensified calls for vaccinations to mitigate COVID-19-related hospitalizations and fatalities.
While the vaccine was developed at an unprecedented speed, concerns around managing booster shot requirements have surfaced under the Trump administration’s FDA.
Senator Ron Johnson, leading inquiries into the government’s pandemic response as the chairman of the Senate Permanent Subcommittee on Inquiries, signaled that his investigation into various Covid-19 topics continues.
His office’s interim report is among several exploring the handling of myocarditis concerns, coinciding with an expected hearing on this matter. Additionally, Johnson’s panel has made public a significant volume of documents collected through subpoenas over the past five years.
The report concluded with a statement on the need to fully reveal the Biden administration’s shortcomings in promptly alerting the public about adverse vaccine events, emphasizing that Americans deserve full transparency regarding the information produced by federal health agencies.
